Table 5:

Differences between treated and untreated patients at 1 year follow up.

	Untreated n = 69		Diflunisal n = 35		p value
	Baseline	1 year follow up	Baseline	1 year follow up
NYHA class					0.46
I	17 (24.6)	3 (4.3)	13 (37.1)	9 (25.7)
II	23 (33.3)	2 (2.9)	16 (45.7)	18 (51.4)
III	26 (37.7)	19 (27.5)	5 (14.3)	6 (17.1)
eGFR, mL/min/1.73m2	53.2 ± 17.6	51.2 ± 20.1	67.3 ± 17.4	59.1 ± 16.7	0.03
BNP, pg/mL	520.1 ± 296.1	595.8 ± 452.7	335.0 ± 365.6	300.5 ± 247.4	0.11
logBNP	6.1 ± 0.7	6.1 ± 0.7	5.5 ± 0.8	5.4 ± 0.8	0.19
Troponin I, ng/mL	0.2 ± 0.34	0.25 ± 0.6	0.1 ± 0.1	0.09 ± 0.07	0.12
LVEF, %	45.0 ± 11.5	43.7 ± 12.9	53.1 ± 12.0	54.1 ± 10.2	0.27
Interventricular septal thickness, mm	15.8 ± 2.3	16.6 ± 2.0	16.6 ± 2.7	17.2 ± 2.33	0.15
Posterior wall thickness, mm	15.8 ± 2.4	16.3 ± 1.9	16.5 ± 2.2	16.7 ± 2.1	0.04

Continuous variables expressed as mean +/− standard deviation and categorical variables as number (%). p values reflect change differences between follow-up and baseline for treated versus untreated patients. eGFR was calculated using the CKD-Epi equation.